OTCMKTS:REVB Revelation Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.04 -0.07 (-6.31%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.91▼$1.0950-Day Range$0.43▼$1.1152-Week Range$0.40▼$11.29Volume3.71 million shsAverage Volume2.44 million shsMarket Capitalization$15.69 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort Interest Revelation Biosciences Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside1,053.8% Upside$12.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.57) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.63 out of 5 stars 3.5 Analyst's Opinion Consensus RatingRevelation Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Revelation Biosciences has a forecasted upside of 1,053.8% from its current price of $1.04.Amount of Analyst CoverageRevelation Biosciences has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for REVB. Previous Next 0.0 Dividend Strength Dividend YieldRevelation Biosciences does not currently pay a dividend.Dividend GrowthRevelation Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for REVB. Previous Next 1.7 News and Social Media Coverage News SentimentRevelation Biosciences has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.Search Interest5 people have searched for REVB on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revelation Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Revelation Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.36% of the stock of Revelation Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revelation Biosciences are expected to decrease in the coming year, from ($0.57) to ($0.66) per share. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Revelation Biosciences (OTCMKTS:REVB)Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company is developing therapeutic product candidates, including REVTx-99a for the prevention or treatment of viral infections, including SARS-CoV-2, variants of SARS-CoV-2, Influenza A, Influenza B, parainfluenza, respiratory syncytial virus, rhinosinusitis, and others; REVTx-99b for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also developing lead diagnostic candidate, such as REVDx-501 to detect various respiratory viral infections. The company is headquartered in San Diego, California.Read More REVB Stock News HeadlinesJune 13, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisMay 23, 2022 | seekingalpha.comSafety committee recommends continuing Revelation's phase 1b trial for hay fever treatmentMay 23, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic RhinitisMay 16, 2022 | seekingalpha.comRevelation Biosciences GAAP EPS of -$0.47May 16, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate ProgressApril 30, 2022 | investing.comRevelation Biosciences Inc (REVB)April 6, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Conference Call to Provide a Corporate UpdateMarch 30, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza InfectionMarch 24, 2022 | finance.yahoo.comRevelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza InfectionMarch 22, 2022 | finance.yahoo.comRevelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLCMarch 15, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza InfectionMarch 8, 2022 | finance.yahoo.comRevelation Biosciences Inc. to Present at the 34th Annual Roth ConferenceFebruary 7, 2022 | finance.yahoo.comRevelation Biosciences Inc. to Present at 2022 BIO CEO & Investor ConferenceJanuary 24, 2022 | finance.yahoo.comRevelation Biosciences Raises $7.76 Million in Equity FinancingJanuary 20, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionJanuary 18, 2022 | finance.yahoo.comRevelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic RhinitisJanuary 13, 2022 | finance.yahoo.comREPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyJanuary 28, 2020 | finance.yahoo.comRevere Bank Announces Record Earnings for 2019 – Net Income of $31.70 Million Increased 14.7% Over 2018's Record EarningsDecember 10, 2019 | finance.yahoo.comShareholder Alert: Ademi & O'Reilly, LLP Investigates whether Revere Bank has obtained a Fair Price in its sale to Sandy Spring Bancorp, Inc.December 10, 2019 | finance.yahoo.comRevere Bank Announces Record Earnings for the Third Quarter of 2019 – Net Income of $8.25 Million Increased 17.7% Over the Third Quarter of 2018July 24, 2019 | finance.yahoo.comRevere Bank Announces Record Earnings for the Second Quarter of 2019 – Net Income of $7.91 Million Increased 15.4% Over the Second Quarter of 2018May 29, 2019 | finance.yahoo.comRevere Bank Announces the Addition of Melanie M. Lundquist, CPA, to Board of Directors, Retirement of Dr. Clayton S. McCarl, Jr., and Kimberly HooverApril 30, 2019 | finance.yahoo.comRevere Bank Announces Record Earnings for the First Quarter of 2019 – Net Income of $7.5 Million Increased 14.5% Over the First Quarter of 2018January 31, 2019 | finance.yahoo.comRevere Bank Announces Fourth Quarter and Annual 2018 Record Earnings – 2018 Net Income of $27.6 Million Increased 69.8% Over 2017See More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:REVB CUSIPN/A CIK1810560 Webwww.revbiosciences.com Phone971-622-5800FaxN/AEmployees2Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+1,053.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2.13 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-12.04% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.30) per share Price / Book-0.24Miscellaneous Outstanding Shares15,083,000Free Float12,081,000Market Cap$15.69 million OptionableNot Optionable Beta2.79 Revelation Biosciences Frequently Asked Questions Should I buy or sell Revelation Biosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Revelation Biosciences stock. View analyst ratings for Revelation Biosciences or view top-rated stocks. What is Revelation Biosciences' stock price forecast for 2022? 1 brokers have issued 1 year price objectives for Revelation Biosciences' stock. Their REVB stock forecasts range from $12.00 to $12.00. On average, they expect Revelation Biosciences' share price to reach $12.00 in the next year. This suggests a possible upside of 1,053.8% from the stock's current price. View analysts' price targets for Revelation Biosciences or view top-rated stocks among Wall Street analysts. How has Revelation Biosciences' stock price performed in 2022? Revelation Biosciences' stock was trading at $22.52 at the beginning of the year. Since then, REVB shares have decreased by 95.4% and is now trading at $1.04. View the best growth stocks for 2022 here. How were Revelation Biosciences' earnings last quarter? Revelation Biosciences, Inc. (OTCMKTS:REVB) released its quarterly earnings data on Monday, May, 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.25. View Revelation Biosciences' earnings history. Who are Revelation Biosciences' key executives? Revelation Biosciences' management team includes the following people: Mr. James M. Rolke, CEO & Director (Age 53, Pay $466.63k)Mr. Chester Stanley Zygmont III, Chief Financial Officer (Age 42, Pay $366.64k)Ms. Sandra Vedrick, VP of HR & Investor RelationsMs. Carol Odle, Sr. Director of Clinical Projects Who are some of Revelation Biosciences' key competitors? Some companies that are related to Revelation Biosciences include Oncotelic Therapeutics (OTLC), BioLineRx (BLRX), Athersys (ATHX), SCYNEXIS (SCYX), Lantern Pharma (LTRN), Mustang Bio (MBIO), BeyondSpring (BYSI), Opiant Pharmaceuticals (OPNT), Verrica Pharmaceuticals (VRCA), Avalo Therapeutics (AVTX), 9 Meters Biopharma (NMTR), Syros Pharmaceuticals (SYRS), Orgenesis (ORGS), Oncolytics Biotech (ONCY) and LifeVantage (LFVN). View all of REVB's competitors. What other stocks do shareholders of Revelation Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revelation Biosciences investors own include Primo Water (PRMW), Almaden Minerals (AAU), AA (AATDF), American Assets Trust (AAT), Advance Auto Parts (AAP), AAON (AAON), Applied Optoelectronics (AAOI), Aaron's (AAN), American Airlines Group (AAL) and AAC Technologies (AACAY). What is Revelation Biosciences' stock symbol? Revelation Biosciences trades on the OTCMKTS under the ticker symbol "REVB." How do I buy shares of Revelation Biosciences? Shares of REVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revelation Biosciences' stock price today? One share of REVB stock can currently be purchased for approximately $1.04. How much money does Revelation Biosciences make? Revelation Biosciences (OTCMKTS:REVB) has a market capitalization of $15.69 million. How many employees does Revelation Biosciences have? Revelation Biosciences employs 2 workers across the globe. How can I contact Revelation Biosciences? The official website for Revelation Biosciences is www.revbiosciences.com. The company can be reached via phone at 971-622-5800. This page (OTCMKTS:REVB) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
